Assembly of mTORC3 involves binding of ETV7 to two separate sequences in the mTOR kinase domain.

Jun Zhan,Frank C Harwood,Sara Ten Have,Angus I Lamond,Priyanka Halder,Richard Kriwacki,Gerard C Grosveld,Aaron Phillips,Monica Cardone

DOI: https://doi.org/10.1101/2024.03.19.583970

2024-07-27

Abstract:mTOR plays a crucial role in cell growth by controlling ribosome biogenesis, metabolism, autophagy, mRNA translation, and cytoskeleton organization. It is a serine/threonine kinase that is part of two distinct extensively described protein complexes, mTORC1 and mTORC2. We have identified a rapamycin resistant mTOR complex, called mTORC3, which is different from the canonical mTORC1 and mTORC2 complexes in that it does not contain the Raptor, Rictor, or mLST8 mTORC1 / 2 components. mTORC3 phosphorylates mTORC1 and mTORC2 targets and contains the ETS transcription factor ETV7, which binds to mTOR and is essential for mTORC3 assembly in the cytoplasm. Tumor cells that assemble mTORC3 have a proliferative advantage and become resistant to rapamycin, indicating that inhibiting mTORC3 may have a therapeutic impact on cancer. Here, we investigate which domains or amino acid residues of ETV7 and mTOR are involved in their mutual binding. We found that the mTOR FRB and LBE sequences in the kinase domain interact with the pointed (PNT) and ETS domains of ETV7, respectively. We also found that forced expression of the mTOR FRB domain in the mTORC3 expressing, rapamycin-resistant cell line Karpas-299 out competes mTOR for ETV7 binding and renders these cells rapamycin-sensitive in vivo. Our data provide useful information for the development of molecules that prevent the assembly of mTORC3, which may have therapeutic value in the treatment of mTORC3 positive cancer.

Cancer Biology

What problem does this paper attempt to address?

### Problems the Paper Attempts to Solve

This paper aims to explore the assembly mechanism of the mTORC3 complex, specifically the amino acid sequences involved in the interaction between ETV7 and mTOR. mTORC3 is a newly discovered mTOR complex that differs from the known mTORC1 and mTORC2, as it does not contain classic components such as Raptor, Rictor, or mLST8. mTORC3 assembles in the cytoplasm and can phosphorylate targets of mTORC1 and mTORC2, providing tumor cells with a proliferative advantage and resistance to rapamycin. Therefore, inhibiting mTORC3 may have potential in cancer therapy.

### Main Research Content

1. **Key Domains of ETV7 and mTOR**:
- Researchers found that the FRB (FKBP-12-rapamycin binding domain) and LBE (mLST8 binding element) sequences of mTOR interact with the PNT (pointed) and ETS (transcription factor binding domain) domains of ETV7, respectively.
- Through mutational analysis, they identified specific amino acid residues in the PNT and ETS domains of ETV7 that are crucial for the assembly of mTORC3.

2. **Assembly Mechanism of mTORC3**:
- Through in vitro and in vivo experiments, researchers confirmed the interaction between the FRB and LBE domains of mTOR and the PNT and ETS domains of ETV7.
- Further experiments showed that overexpression of the FRB domain of mTOR can competitively interfere with the binding of mTOR to ETV7, thereby resensitizing Karpas-299 cells, which were originally resistant to rapamycin.

3. **Potential Therapeutic Applications**:
- By identifying the specific amino acid sequences involved in the assembly of mTORC3, researchers provided crucial foundational information for designing small molecule inhibitors targeting mTORC3, which may aid in developing new cancer therapies.

### Conclusion

This study elucidates the specific mechanisms of interaction between ETV7 and mTOR, providing important insights into the assembly process of mTORC3. These findings not only enhance the understanding of the mTOR signaling pathway but also provide a theoretical basis for developing new anti-cancer drugs targeting mTORC3.